News and Conferences

1

  1. AD/PD 2023

    AD/PD March 28th - April 1st 2023, Gothenburg, Sweden AD/PD is the world renowned international conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
    Read more

  2. OARSI World Congress

    17th - 20th March; Denver, USA Scientists and health care professionals focused on the prevention and treatment of osteoarthritis meet at the OARSI World Congress.
    Read more

  3. Veterinary Meeting and Expo

    Reputed to be the largest veterinary conference, covering small animal and large animal track topics, as well as education, nurse, technician and practice management, VMX is being held in Orlando, USA between January 14th-18th. We are looking forward to attending and talking about the opportunities offered by Transpharmation’s sister company, CanCog Technologies.
    Read more

  4. New published work!

    Coinciding with World Diabetes Day, 14th November, is the publication of our work, ‘Induction of Type I Diabetes Mellitus in Beagle Dogs Using Alloxan and Streptozotocin’. Important insight that takes us nearer to enhanced translatability to the human health field.
    Read more

  5. Name change announcement, news from the CEO

    It has now been just over a year since InterVivo Solutions (headquartered in Toronto, Canada) acquired Transpharmation, (headquartered in London, UK) bringing together two Neuroscience-centric Contract Research Organisations (CROs). This has enabled us to deliver a wider set of capabilities, along with an even deeper knowledge base, to assist our clients in the Global Pharmaceutical, Animal Health and Biotech Sectors.
    Read more

  6. Society for Neuroscience 2022, November 12-16, California

    This year’s prestigious event is taking place at the San Diego Convention Centre in San Diego, CA. We are looking forward to seeing familiar faces and meeting new ones. Covering a number of our translational services, we will have several posters on display, along with several members of our scientific team on hand to answer questions, hold meetings and update you on the latest developments that we are able to offer you. Keep an eye on our Linkedin profile for more details coming out soon.

    Read more

  7. CNS Therapeutic Xchange Europe 2022, Zurich - 24th November

    Transpharmation's Scientific Lead for EEG, Sleep and Epilepsy, Sandor Kantor PhD, will be making a spotlight presentation on the 24th of November at 13.20-13.50. His presentation is titled 'The effect of CNS-acting drugs on rodent mismatch negativity is modulated by vigilance states' and will expand on the following aspects: Mismatch negativity (MMN) is a component of event-related potentials that is diminished in many neuropsychiatric disorders including schizophrenia; Central nervous system (CNS)-acting drugs often alter vigilance states, and it is not well understood how the drug-induced changes in sleep-wake behaviour affect MMN generation; An overview of the recent rodent MMN research with a special focus on vigilance state specific changes and discuss the methodological aspects and future implications of the latest findings.

    For further information about this event please see here:

    https://www.hub-xchange.com/cns-therapeutics-xchange-europe-2022/#anchor1 

    To view the presentation after the event please contact us. 

    Read more

  8. Here, there and everywhere - we love meeting up with you!

    Digital conferences were a useful solution during the periods of lockdown, but there is nothing that quite replaces presenting the results of new studies and meeting with customers old and new in a face to face environment.
    Read more

  9. ECNP Congress, 15th-18th October - Vienna, Austria

    The annual ECNP Congress is Europe’s premier scientific meeting for disease-oriented brain research, annually attracting more than 5,000 psychiatrists, neuroscientists, neurologists and psychologists from around the world. Transpharmation will be presenting two posters; (1) Differential effects of repeated treatment with DOI and psilocybin on the head-twitch response (HTR), locomotor activity and anxiety-like behaviour and (2) 2,5-Dimethoxy-4-iodoamphetamine (DOI) enhances motivation in low and medium but not high performers in the progressive ratio (PR) task in rats. We look forward to seeing you, but if you are unable to attend this event, we will make the posters available to you on our publications page after October 18th. For more details, please feel free to contact us.

    Read more

  10. Recent collaborative work published by Frontiers in Molecular Neuroscience

    Frontiers in Molecular Neuroscience have recently published Transpharmation's collaborative research with Cindy Périer, Amy Fisher and Mikhail Kalinichev, exploring the efficacy of BoNT/A for inflammatory Pain in Mice.  For over three decades, BoNT/A (botulinum neurotoxin Type A) has been used to treat muscle hyperactivity. Following studies in animals demonstrating inhibition of pain transmitters at peripheral and central levels, BoNTs have also been explored in a growing range of human pain conditions as potential analgesic agents. You can read it here: Frontiers in Molecular Neuroscience. For further information about this study or to enquire about booking in your work with us please contact us.
    Read more
1

Want to see our latest study results?

Sign up for our newsletter.

Newsletters